Pomalidomide, bortezomib, and dexamethasone for patients with relapsed lenalidomide-refractory multiple myeloma

This phase 1/2 trial evaluated the maximum tolerated doses, safety, and efficacy of pomalidomide, bortezomib, and dexamethasone (PVD) combination in patients with relapsed lenalidomide-refractory multiple myeloma (MM). In phase 1, dose level 1 consisted of pomalidomide (4 mg by mouth on days 1 to 21...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Blood
Hlavní autoři: Paludo, Jonas, Mikhael, Joseph R., LaPlant, Betsy R., Halvorson, Alese E., Kumar, Shaji, Gertz, Morie A., Hayman, Suzanne R., Buadi, Francis K., Dispenzieri, Angela, Lust, John A., Kapoor, Prashant, Leung, Nelson, Russell, Stephen J., Dingli, David, Go, Ronald S., Lin, Yi, Gonsalves, Wilson I., Fonseca, Rafael, Bergsagel, P. Leif, Roy, Vivek, Sher, Taimur, Chanan-Khan, Asher A., Ailawadhi, Sikander, Stewart, A. Keith, Reeder, Craig B., Richardson, Paul G., Rajkumar, S. Vincent, Lacy, Martha Q.
Médium: Artigo
Jazyk:Inglês
Vydáno: American Society of Hematology 2017
Témata:
Clinical Trials and Observations
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5606008/
https://ncbi.nlm.nih.gov/pubmed/28684537
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2017-05-782961
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky